Market Research Logo

»»

Global Primary Sclerosing Cholangitis Treatment Market 2018-2022

Lowest Prices Guaranteed Length Publisher Published Date SKU
from $2,500 110 Pages TechNavio - Infiniti Research Ltd. August, 2018 INF15767344
Lowest Prices Guaranteed
Price from $2,500
Length 110 Pages
Publisher TechNavio - Infiniti Research Ltd.
Published Date August, 2018
SKU INF15767344
$2,500
$3,000
$4,000
$5,000
 
Research assistance
US: 800.298.5699
Int'l: +1.240.747.3093

Global Primary Sclerosing Cholangitis Treatment Market 2018-2022

About Primary Sclerosing Cholangitis

Primary sclerosing cholangitis is chronic liver disease that can occur either by itself or due to other diseases. The disease is characterized by the inflammation and thickening of the bile ducts. This obstructs bile flow, which may lead to other liver diseases.

Technavio’s analysts forecast the Global Primary Sclerosing Cholangitis Treatment Market to grow at a CAGR of 3.57% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the primary sclerosing cholangitis treatment market. To calculate the market size, the report considers the revenue generated from the primary sclerosing cholangitis treatment across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, primary sclerosing cholangitis treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Allergan
  • Glenmark
  • Impax Laboratories
  • Mylan
  • Teva Pharmaceuticals
Market driver
  • Rise in number of liver transplants and UDCA treatment
  • For a full, detailed list, view our report
Market challenge
  • Poor understanding of PSG pathogenesis
  • For a full, detailed list, view our report
Market trend
  • Development of affordable PSC drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Primary sclerosing cholangitis
  • Market landscape
    • Market ecosystem
      • Table Parent market
      • Table Global metabolic disorder therapeutic market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global – Market size and forecast 2017-2022 ($ mn)
      • Table Global – Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2017
  • Pipeline landscape
    • Table Pipeline landscape by development phase
    • Table Key clinical trials candidates of primary sclerosing cholangitis
  • Market segmentation by product
    • Segmentation by product
      • Table Product – Market share 2017-2022 (%)
    • Comparison by product
      • Table Comparison by product
    • UDCA – Market size and forecast 2017-2022
      • Table UDCA – Market size and forecast 2017-2022 ($ mn)
      • Table UDCA – Year-over-year growth 2018-2022 (%)
    • Others – Market size and forecast 2017-2022
      • Table Others – Market size and forecast 2017-2022 ($ mn)
      • Table Others – Year-over-year growth 2018-2022 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global – Market share by geography 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • Americas – Market size and forecast 2017-2022
      • Table Americas – Market size and forecast 2017-2022 ($ mn)
      • Table Americas – Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in Americas
    • EMEA – Market size and forecast 2017-2022
      • Table EMEA – Market size and forecast 2017-2022 ($ mn)
      • Table EMEA – Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in EMEA
    • APAC – Market size and forecast 2017-2022
      • Table APAC – Market size and forecast 2017-2022 ($ mn)
      • Table APAC – Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Development of affordable PSC drugs
    • Surrogate endpoints for clinical trials in PSC
    • siRNA therapeutic products for treatment of PSC
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • ALLERGAN
      • Table ALLERGAN – Overview
      • Table ALLERGAN – Business segments
      • Table ALLERGAN – Organizational developments
      • Table ALLERGAN – Geographic focus
      • Table ALLERGAN – Segment focus
      • Table ALLERGAN – Key offerings
      • Table ALLERGAN – Key customers
    • Glenmark
      • Table Glenmark – Overview
      • Table Glenmark – Business segments
      • Table Glenmark– Organizational developments
      • Table Glenmark – Geographic focus
      • Table Glenmark – Segment focus
      • Table Glenmark – Key offerings
      • Table Glenmark – Key customers
    • Impax Laboratories
      • Table Impax Laboratories – Overview
      • Table Impax Laboratories – Business segments
      • Table Impax Laboratories – Organizational developments
      • Table Impax Laboratories – Geographic focus
      • Table Impax Laboratories – Segment focus
      • Table Impax Laboratories – Key offerings
      • Table Impax Laboratories – Key customers
    • Mylan
      • Table Mylan – Overview
      • Table Mylan – Business segments
      • Table Mylan – Organizational developments
      • Table Mylan – Geographic focus
      • Table Mylan – Segment focus
      • Table Mylan – Key offerings
      • Table Mylan – Key customers
    • TEVA Pharmaceutical
      • Table TEVA Pharmaceutical – Overview
      • Table TEVA Pharmaceutical – Business segments
      • Table TEVA Pharmaceutical – Organizational developments
      • Table TEVA Pharmaceutical – Geographic focus
      • Table TEVA Pharmaceutical – Segment focus
      • Table TEVA Pharmaceutical – Key offerings
      • Table TEVA Pharmaceutical – Key customers
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

Other tasks